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androgen synthesis. In a preplanned interim analysis of the Phase 3 trial COU-
AA-301, AA plus prednisone (P) showed a significant overall survival (OS) benefit 
of 3.9 months vs placebo plus P (de Bono, NEJM 2011). A preplanned and updated 
analysis showed that the improvement in median OS increased from 3.9 months 
to 4.6 months (HR = 0.74) (Fizazi, Lancet Oncol 2012). The purpose of this study 
was to evaluate the cost effectiveness of AA vs P using data from Swedish 
patients. METHODS: A survival-based decision analysis model was developed 
incorporating 3 health states: progression-free survival, post-progression 
survival, and OS (indirect comparison). The cost-effectiveness model was 
populated with data from one placebo-controlled randomized clinical trial in 
which AA was an add-on to P (de Bono, NEJM 2011), and treatment duration from 
the name-patient-programme (NPP) in Sweden for patients with metastatic 
castrate-resistant prostate cancer post-docetaxel. Resource utilization and costs 
reflected Swedish treatment conditions within a broad societal perspective. Drug 
costs per 3-week-model-cycle were $3180 (€2300) and $53 (€41) for AA and P, 
respectively. RESULTS: Total costs per patient were $85270 (€67300) and $52700 
(€41600) for AA and P, respectively. Quality-adjusted life years (QALYs) were 1.24 
and 0.77 for AA and P, respectively. CONCLUSIONS: The results show that AA 
treatment compared to P has a cost per QALY gained of $69800 (€55000). AA 
provides an OS benefit with a highly manageable and benign safety profile, 
compared to P, which has negligible effects on OS and QoL.  
 
PCN41  
THE DIRECT HEALTH CARE COST OF PROSTATE CANCER: EVIDENCE FROM US 
NATIONAL SURVEY DATA  
Mallow PJ1, Chen J2, Rizzo JA3, Zyczynski TM4, Penrod JR5, Trudel GC6 
1S2 Statistical Solutions, Cincinnati, OH, USA, 2University of Maryland, College Park, MD, USA, 
3Stony Brook University, Port Jefferson, NY, USA, 4Bristol-Myers Squibb, Princeton, NJ, USA, 
5Bristol-Myers Squibb, Plainsboro, NJ, USA, 6Bristol-Myers Squibb, Montréal, QC, Canada  
OBJECTIVES: Approximately 2.8 million American men have a history of prostate 
cancer, the most prevalent cancer among men in the US. This study quantified 
the effects of prostate cancer on direct health care costs to insurers and patients. 
METHODS: Using data 1996-2009 from the Medical Expenditure Panel Survey 
(MEPS), a large, nationally-representative database from the US, this study 
performed multivariate analyses of the relationship between prostate cancer and 
direct annual health care costs to insurers and patients, at individual and US 
aggregate levels. All men age 40 and older with International Classification of 
Disease Codes, 9th revision of 185 were identified. RESULTS: The MEPS database 
included 1,399 patients with prostate cancer. Mean age was 72 years, and 71% 
were Caucasian. Prostate cancer patients incurred $9,300 more in overall annual 
health care costs per patient when compared to non-prostate cancer patients 
($18,423 vs. $9,093). The majority of direct health care costs were borne by the 
insurer ($8,900) rather than the patient ($430). Prostate cancer had a larger effect 
on incremental costs for younger patients ($16,253 40-64 years vs. $10,236 65-74 
years; $7,767 75+ years). When aggregated to the US population, prostate cancer 
accounted for an incremental annual cost of $14.27 billion. The largest aggregate 
costs were incurred by patients aged 40-64 years ($5.33 billion), compared to 
those aged 65-74 ($4.86 billion) and patients aged 75+ ($4.08 billion). 
CONCLUSIONS: These findings indicate that the cost burden from prostate 
cancer is quite large. Younger patients incur more direct health care costs, 
possibly due to more aggressive treatment practices, which may be related to 
more aggressive tumor burden. With aging of the population, prevalence of 
prostate cancer is expected to increase to 3.2 million in the US in 2020. Further 
research to understand these cost implications is warranted.  
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OBJECTIVES: In terms of indirect cost, prostate cancer appears to have an 
adverse impact on work performance, due to the use of sick days by patients in 
the period after diagnosis. This study quantified the effects of prostate cancer on 
indirect costs related to work absence and unemployment among individuals 
age 40 and older. METHODS: Using 1996-2009 data from the Medical Expenditure 
Panel Survey (MEPS), a large, nationally-representative database from the US, we 
performed multivariate analyses evaluating the relationship between prostate 
cancer and indirect costs, at the individual and US aggregate levels. All men with 
International Classification of Disease Codes, ninth revision of 185 were 
identified. Costs by 2 age categories (40-64 years, 65+ years) were explored. 
Indirect costs were defined as lost worker productivity resulting from being 
unemployed or days of missed work as a result of illness. RESULTS: The MEPS 
database included 1,399 patients with prostate cancer. Mean age was 72 years, 
and 71% were Caucasian. Prostate cancer patients had a greater probability of 
being unemployed (40% vs. 34%) and a greater probability of missing work due to 
illness (68% vs. 47%) than non-prostate cancer patients. Employed patients with 
prostate cancer missed 9.3 more work days than individuals without prostate 
cancer (19.5 vs. 10.2). This resulted in an incremental indirect cost of $2936 per 
patient. Indirect costs due to prostate cancer were higher for patients aged 40-64 
than patients aged 65+ ($6848 versus $1581). When aggregated to the  
US population, prostate cancer accounted for $4.21 billion in indirect costs,  
with $2.68 billion for patients aged 40-64 and $1.53 billion for patients aged 65 
and older. CONCLUSIONS: These findings indicate that the indirect cost burden 
from prostate cancer is quite large, especially for younger patients. Further 
research is needed to determine the impact of disease severity on productivity-
related costs.  
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OBJECTIVES: Treatment patterns and cost of care are believed to vary 
substantially as patients with colorectal cancer (CRC) progress from first line 
through third line therapy. The aim of this study was to examine patterns and 
cost of care in these patients. METHODS: A retrospective analysis was performed 
using claims from the Optum Oncology Research Database. Patients aged 18 
years and older, diagnosed with CRC between July 1, 2004 and December 31, 
2010, who were insured by a commercial health plan were included in the study. 
Chemotherapy combinations were assessed for patients receiving first, second 
and third line of therapy for CRC; and for patients with and without metastatic 
disease. Inpatient, outpatient, chemotherapy, biologic-related, and total costs 
were compared by the Kruskal-Wallis test. RESULTS: A total of 1039 patients 
who received chemotherapy or biologic therapy for CRC were included. FOLFOX 
and fluorouracil monotherapy were the most common first-line therapies, each 
accounting for approximately 27% of patients who received any chemotherapy. 
Oxaliplatin-based regimens were most common for patients receiving second-
line therapy (45% of patients). Irinotecan-based regimens were most common 
among patients receiving third line therapy (35% of patients). The median total 
cost of care increased significantly for patients receiving first ($25,782), second 
($36,951), and third ($86,944) line therapy (p<0.0001 by Kruskal-Wallis test). 
Median costs were significantly greater for patients receiving third versus first 
line therapy for outpatient care ($39,952 vs. $15,521), inpatient care ($3,668 vs. 
$1,721 vs.), chemotherapy ($14,059 vs. $3,662) and biologic therapy ($28,824 vs. 
$4,899). Median total were significantly greater for patients with metastases 
($39,001) compared with those without ($8,989; p<0.0001). CONCLUSIONS: 
Treatment patterns vary significantly by line of therapy in patients with CRC. 
The total cost of care increased significantly as patients received additional lines 
of therapy and is significantly greater for patients with metastases compared to 
those without.  
 
PCN44  
DIRECT MEDICAL COSTS OF CARCINOMA OF KIDNEY IN CHINA  
Wu J1, Zhu G2, Gao S3, Wu J3 
1Peking University, Beijing, China, 2Bayer Healthcare Company Ltd., Beijing, Beijing, China, 
3Beijing Brainpower Pharma Consulting Co. Ltd, BeiJing, China  
OBJECTIVES: Carcinoma of kidney (or renal cell carcinoma) is one common 
tumor for adults. The purpose of this study was to evaluate the direct costs of 
patients with carcinoma of kidney in China, producing an average cost per 
patient per year and the overall economic burden of the whole carcinoma of 
kidney population. METHODS: A cost-of-illness analysis was then performed. 
The Chinese Basic Medical Insurance Databases in 2010 were used to collect data 
on health care resource utilization and costs. 224 patients diagnosed with 
carcinoma of kidney were randomly selected by stratified two-stage sampling. 
All information of patient demographic characters, clinical and costs were 
collected for the analysis. Direct medical costs included were diagnostic tests, 
physiotherapy, surgery, drug and administration costs. The descriptive statistics 
was used to describe patients’ demographic characters and costs. Prevalence 
data on carcinoma of kidney for the Chinese population was collected from 
literatures. The overall economic burden of the whole carcinoma of kidney 
population was estimated based on the costs per patient per year and the 
prevalence data. All costs referred to 2010. RESULTS: Total 224 patients (mean 
age 60.9 years; 72.6% male) were evaluated. Total costs per patient over 1 year 
amounted to Chinese Yuan (CNY) 17,366 (median: CNY15750, IQR: CNY7773 –
CNY26285), with drug costs accounting for 50.14% of the total. Based the 
prevalence of carcinoma of kidney from literatures, there was about 74,809 
patients of carcinoma of kidney. Costs for the nation are estimated at CNY 0.389 
billion per year. CONCLUSIONS: The economic burden of carcinoma of kidney in 
China is considerable. The primary burden on patients was due to drugs.  
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OBJECTIVES: This study quantified the “spillover” effects of prostate cancer on 
indirect costs related to work absence and unemployment among spouses and 
other family members residing with prostate cancer patients, a topic that has 
received little attention in the literature. METHODS: Using 1996-2009 data from 
the Medical Expenditure Panel Survey (MEPS), a large, nationally-representative 
database from the US, this study performed multivariate analyses evaluating the 
relationship between prostate cancer and the indirect costs to family members 
and spouses of prostate cancer patients. Indirect costs were defined as lost 
worker productivity resulting from being unemployed or missed work-days as a 
result of prostate cancer. Spillover effects were calculated for all individual 
family members (including spouses) and for spouses separately, and projected to 
the US population. RESULTS: The MEPS database included data for 1,399 patients 
with prostate cancer, 1,121 family members and 874 spouses. Family members of 
prostate cancer patients were found to have incurred $1,319 in annual indirect 
